Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Completed · Phase 3 · Has a placebo group
Conditions studied: Macular Degeneration
In brief
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
Key facts
- Study ID
- NCT00041483
- Run by
- Alcon Research
- People needed
- 530
- Starts
- 2002-06-01
- Expected to finish
- 2005-08-01
- Last updated by the study team
- 2014-07-01
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Contact Alcon Call Center for Trial Locations — Fort Worth, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.